The Company That Made IVF an Employee Benefit
How a fertility website became a Nasdaq-listed benefits company covering millions of employees - and why big employers hand Progyny the hardest part of their health plan.
For decades, fertility treatment was the line item health plans quietly left out. Cancer, cardiology, orthopedics - all covered. In vitro fertilization, if it appeared at all, showed up as a small dollar cap: ten thousand dollars, maybe, then good luck. Progyny built a company on the premise that this gap was not just unfair but bad business, and that the employers competing hardest for talent would pay to close it.
Today Progyny, Inc. is a New York company trading on the Nasdaq under the ticker PGNY, reporting more than $1.1 billion in annual revenue and selling fertility, family-building and women's-health benefits to some of the largest employers in the country. Its clients read like a roster of the technology industry - Google, Microsoft, Amazon, Meta, Salesforce - and its members number in the millions. What Progyny sells, in essence, is the ability for an HR department to hand off one of the messiest, most emotional and most expensive corners of the health plan to someone who has decided to specialize in it.
01 / OriginsFrom a website to a benefit
The company did not start as a benefits provider. It began in 2008 as FertilityAuthority, an online information and referral platform founded by Gina Bartasi to help people navigate a confusing field. In 2015 that business merged with Auxogyn, a fertility-technology company, and the combined entity took the name Progyny. The pivot that mattered came the following year, when former WebMD chief executive David Schlanger took over and pointed the company at employers rather than consumers.
The early going was not glamorous. In Schlanger's own account, the company had to persuade doctors to participate at all. It signed five clients in 2016. The bet was that if Progyny could prove better outcomes and package the benefit cleanly, demand would follow. It did.
02 / The ProductThe Smart Cycle, and why the cap had to go
The centerpiece of Progyny's offering is a deceptively simple idea called the Smart Cycle. Instead of giving employees a dollar amount to spend - which forces patients and doctors to ration mid-treatment - Progyny bundles care into roughly 19 customizable treatment units covering diagnostics, genetic testing and procedures, with no dollar maximum. A member gets a complete course of treatment rather than a partial one. Employers typically buy two or three cycles per member.
Around that core sit the other pieces of the model. Progyny Rx, launched in 2018, is an in-house fertility pharmacy that manages the notoriously complicated and costly medication regimens these treatments require, cutting drug cost and waste and shipping quickly. It has grown into roughly a third of company revenue. And every member is assigned a Patient Care Advocate - a person with a clinical, nursing or social-work background who guides them through the process, averaging around 15 touchpoints per cycle.
Where the revenue comes from
03 / The ArgumentSelling on outcomes, not price
Plenty of vendors will sell an employer a fertility benefit. Progyny's pitch is that its version produces better medical results, and it leans on independently validated data to make the case. The company reports IVF live-birth rates well above the national average, a lower miscarriage rate, and dramatically fewer multiple births - the twins and triplets that drive the highest-risk, highest-cost pregnancies. Fewer multiples is better for families and, not incidentally, cheaper for the employer footing the bill.
That data is possible because Progyny curates its network rather than accepting everyone. It manages a group of more than a thousand specialists to inclusion and quality standards, and reports that its network includes the large majority of the country's leading clinics. The result is a virtuous loop the former chief executive described bluntly.
04 / The BusinessHow Progyny gets paid
The model is business-to-business. Progyny sells to large, mostly self-insured employers - generally those with at least a thousand covered lives - and books revenue from two streams: the fertility benefit services themselves and the Progyny Rx pharmacy. It is not a consumer app and it does not, in the main, bill patients. Its customer is the benefits leader who wants a cleaner, better-performing program and a single vendor to run it.
Annual Revenue
Progyny's reported top line, in US dollars. FY2024 crossed $1.16 billion; 2025 guidance ran to roughly $1.2 billion.
Progyny went public in October 2019, pricing its IPO at $13 a share and watching the stock climb about 23 percent on its first day of trading. By late 2025 the company carried a market capitalization in the neighborhood of $2.2 billion, with FY2024 adjusted EBITDA of roughly $199 million on that $1.167 billion in revenue.
05 / The ExpansionBeyond fertility
Having established itself in fertility, Progyny has been widening the definition of what it sells. It has added pregnancy and postpartum care - including doula services introduced in 2025 through a partnership with Pacify - along with menopause and midlife programs, and reimbursement for adoption and surrogacy. In 2025 it also introduced Progyny Select, described as a fully insured supplemental plan, and began extending programs to multinational employers for 2026. The logic is familiar to anyone who has watched a successful platform grow: land one benefit, then become the vendor of record for the whole category of women's and reproductive health.
The market took notice in a pointed way in June 2025, when Amazon named Progyny the first women's health and family-building solution in its Health Benefits Connector program. When the company that has reshaped so many supply chains vets your benefit and puts it on a shelf for other employers, that is a signal worth reading.
06 / The FieldWhere Progyny sits
Progyny is not alone. Carrot Fertility, Maven Clinic, Kindbody, WINFertility, Stork Club and Cleo all compete for employer contracts in fertility and family building, each with a different emphasis - some more digital-first, some more clinic-owned. Progyny's distinguishing claim is the combination of a curated specialist network, the concierge care-advocate layer, and outcomes data it can hand to a skeptical buyer. In a category where the product is trust as much as coverage, measurable results are the argument.
For all the financial machinery, the thing Progyny is selling is fairly human: the chance for an employee to go through one of the hardest experiences of their life with a real person on the phone, a good clinic in reach, and no dollar cap cutting treatment short. That it turned out to be a billion-dollar business says as much about what health insurance historically ignored as it does about the company that stepped into the gap.